215 related articles for article (PubMed ID: 35575257)
1. Severe atopic dermatitis in a 21-month-old boy successfully treated with dupilumab.
Mazzoni D; Lobo Y; Levitt D; Wheller L
Pediatr Dermatol; 2022 Jul; 39(4):606-608. PubMed ID: 35575257
[TBL] [Abstract][Full Text] [Related]
2. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
3. Prurigo-like atopic dermatitis in a child with CARD11-associated severe combined immunodeficiency successfully treated with dupilumab.
Gualdi G; Lougaris V; Amerio P; Petruzzellis A; Parodi A; Burlando M
Pediatr Dermatol; 2024; 41(1):158-159. PubMed ID: 37888582
[TBL] [Abstract][Full Text] [Related]
4. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E
J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
7. Occupational Chronic Contact Dermatitis Successfully Treated with Dupilumab: A Case Series.
Slodownik D; Levi A; Lapidoth M; Moshe S
Dermatology; 2022; 238(6):1073-1075. PubMed ID: 35462358
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
[TBL] [Abstract][Full Text] [Related]
9. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series.
Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab use in atopic dermatitis and beyond in skin diseases.
Fourzali K; Golpanian RS; Yosipovitch G
Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
14. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
15. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
16. Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].
Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
J Cutan Med Surg; 2020; 24(5):468-473. PubMed ID: 32442020
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
18. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
[TBL] [Abstract][Full Text] [Related]
19. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
20. Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis.
Hendricks AJ; Lio PA; Shi VY
Am J Clin Dermatol; 2019 Aug; 20(4):565-569. PubMed ID: 30919315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
